ArticleJournal of translational medicine2025
Schistosoma japonicum peptide SJMHE1 promotes peripheral nerve regeneration via macrophage migrasome-derived miR-26b-5p targeting the PTEN/AKT axis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Whole-transcriptome sequencing reveals hypoxic esophageal squamous cell carcinoma-derived migrasomes driving cancer-associated fibroblast activation.Briefings in functional genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPeripheral nerve injury (PNI) is a major clinical challenge with limited effective therapeutic options. Our prior work has demonstrated that SJMHE1, a peptide derived from Schistosoma japonicum, promotes peripheral nerve regeneration by regulating M2 macrophages; however, its downstream molecular mechanisms remain unclear. Migrasomes are newly identified migration-dependent extracellular vesicles that mediate intercellular communication, and are abundantly produced by highly migratory macrophages. The present study investigates whether SJMHE1 promotes peripheral nerve regeneration through macrophage-derived migrasomes, with a focus on the role of these migrasomes in macrophage-Schwann cell crosstalk.
methodsThe formation of migrasomes was observed using an in vivo rat model of sciatic nerve transection injury and in vitro macrophage-Schwann cell co-culture systems. SJMHE1-induced macrophage-derived migrasomes (SM-M) were systematically characterized: transmission electron microscopy (TEM) for morphological analysis, nanoparticle tracking analysis (NTA) for size distribution, and Western blotting (WB) for detecting migrasome marker proteins (e.g., TSPAN4, PIGK). The regulatory effects of SM-M on Schwann cell function were evaluated using multiple approaches: CCK-8 and EdU assays to assess cell proliferation, Transwell assays to measure cell migration in vitro; and a rat sciatic nerve crush injury model to verify in vivo regenerative effects (via immunofluorescence staining for S100 and NF200). Additionally, miRNA sequencing was performed on SM-M to identify key miRNAs and subsequent bioinformatics analysis was conducted to elucidate the potential molecular mechanisms by which SM-M regulates Schwann cell function.
resultsSJMHE1 treatment significantly enhances migrasome production in macrophages under both the in vivo and in vitro conditions. Functional experiments revealed that SM-M improve Schwann cell function in vivo and significantly promote the proliferation and migration of Schwann cells in vitro. Mechanistically, SM-M deliver miR-26b-5p to directly target and inhibit PTEN expression, thereby activating the AKT signaling pathway to regulate Schwann cell proliferation and migration.
conclusionOur findings reveal a novel mechanism by which SJMHE1 promotes peripheral nerve regeneration through macrophage-Schwann cell communication mediated by miRNA delivery via macrophage migrasomes. This study highlights SJMHE1 as a promising therapeutic peptide for PNI and indicates that targeting migrasome-mediated communication between macrophages and Schwann cells may represent a new therapeutic strategy for PNI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.